Update on the use of Trandolapril in the management of cardiovascular disorders
Ariel Diaz1, Anique Ducharme21University of Montreal, Trois-Rivieres; 2Department of Medicine, Montreal Heart Institute Research Center, Montreal, Quebec, CanadaAbstract: Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objecti...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-12-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/update-on-the-use-of-trandolapril-in-the-management-of-cardiovascular--peer-reviewed-article-VHRM |
| _version_ | 1819084160767098880 |
|---|---|
| author | Ariel Diaz Anique Ducharme |
| author_facet | Ariel Diaz Anique Ducharme |
| author_sort | Ariel Diaz |
| collection | DOAJ |
| description | Ariel Diaz1, Anique Ducharme21University of Montreal, Trois-Rivieres; 2Department of Medicine, Montreal Heart Institute Research Center, Montreal, Quebec, CanadaAbstract: Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine. Various populations have been studied in large clinical trials including patients with congestive heart failure (CHF) after an acute myocardial infarction (AMI), diabetics, patients with hypertension (HTN), stable coronary artery disease (CAD) and prevention of proteinuria. Long-term treatment with trandolapril in patients with reduced left ventricular function soon after AMI significantly reduced the risk of overall mortality, mortality from CV causes, sudden death, and the development of severe CHF. Treatment with trandolapril after AMI complicated by left ventricular dysfunction appears to be of considerable importance in patients with diabetes mellitus by saving lives and substantially reducing the risk of progression to severe CHF as well. Moreover, trandolapril reduces progression to proteinuria in high-risk patients. Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration.Keywords: trandolapril, angiotensin converting enzyme inhibitors, hypertension cardiovascular diseases, diabetic nephropathy |
| first_indexed | 2024-12-21T20:44:03Z |
| format | Article |
| id | doaj.art-01a46c9c2ec44800be6dc17a5ea54ab9 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-21T20:44:03Z |
| publishDate | 2008-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-01a46c9c2ec44800be6dc17a5ea54ab92022-12-21T18:50:52ZengDove Medical PressVascular Health and Risk Management1178-20482008-12-01Volume 4114711582484Update on the use of Trandolapril in the management of cardiovascular disordersAriel DiazAnique DucharmeAriel Diaz1, Anique Ducharme21University of Montreal, Trois-Rivieres; 2Department of Medicine, Montreal Heart Institute Research Center, Montreal, Quebec, CanadaAbstract: Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine. Various populations have been studied in large clinical trials including patients with congestive heart failure (CHF) after an acute myocardial infarction (AMI), diabetics, patients with hypertension (HTN), stable coronary artery disease (CAD) and prevention of proteinuria. Long-term treatment with trandolapril in patients with reduced left ventricular function soon after AMI significantly reduced the risk of overall mortality, mortality from CV causes, sudden death, and the development of severe CHF. Treatment with trandolapril after AMI complicated by left ventricular dysfunction appears to be of considerable importance in patients with diabetes mellitus by saving lives and substantially reducing the risk of progression to severe CHF as well. Moreover, trandolapril reduces progression to proteinuria in high-risk patients. Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration.Keywords: trandolapril, angiotensin converting enzyme inhibitors, hypertension cardiovascular diseases, diabetic nephropathyhttps://www.dovepress.com/update-on-the-use-of-trandolapril-in-the-management-of-cardiovascular--peer-reviewed-article-VHRMtrandolaprilangiotensin converting enzyme inhibitorshypertension cardiovascular diseasesdiabetic nephropathy |
| spellingShingle | Ariel Diaz Anique Ducharme Update on the use of Trandolapril in the management of cardiovascular disorders Vascular Health and Risk Management trandolapril angiotensin converting enzyme inhibitors hypertension cardiovascular diseases diabetic nephropathy |
| title | Update on the use of Trandolapril in the management of cardiovascular disorders |
| title_full | Update on the use of Trandolapril in the management of cardiovascular disorders |
| title_fullStr | Update on the use of Trandolapril in the management of cardiovascular disorders |
| title_full_unstemmed | Update on the use of Trandolapril in the management of cardiovascular disorders |
| title_short | Update on the use of Trandolapril in the management of cardiovascular disorders |
| title_sort | update on the use of trandolapril in the management of cardiovascular disorders |
| topic | trandolapril angiotensin converting enzyme inhibitors hypertension cardiovascular diseases diabetic nephropathy |
| url | https://www.dovepress.com/update-on-the-use-of-trandolapril-in-the-management-of-cardiovascular--peer-reviewed-article-VHRM |
| work_keys_str_mv | AT arieldiaz updateontheuseoftrandolaprilinthemanagementofcardiovasculardisorders AT aniqueducharme updateontheuseoftrandolaprilinthemanagementofcardiovasculardisorders |